Skip to main content

Bristol-Myers Squibb's $74B deal for Celgene criticized, called risky

At least one shareholder said the $74 billion deal is "poorly conceived and ill-advised."
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.